RenovoRx (RNXT) Gains from Investment Securities (2023 - 2026)
RenovoRx (RNXT) posted Gains from Investment Securities of $97000.0 for Q1 2026, up 119.17% sequentially from -$506000.0 in Q4 2025, and up 116.61% YoY from $44781.0 in Q1 2025.
RenovoRx (RNXT) Gains from Investment Securities (2023 - 2026) Analysis & Trends
RenovoRx has reported Gains from Investment Securities for 4 years, with the latest figure at $97000.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 116.61% year-over-year to $97000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$234000.0 (up 76.44% YoY) and the FY2025 annual result came in at -$915000.0, up 48.36% from the prior year.
- Gains from Investment Securities rose to $97000.0 in Q1 2026 per RNXT's latest filing, from -$506000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.4 million in Q4 2023 and troughed at -$1.4 million in Q1 2024.
- A 4-year average of -$212000.0 and a median of -$233000.0 in 2024 frame the typical range for Gains from Investment Securities.
- The widest YoY moves for Gains from Investment Securities: up 169.03% in 2025, down 252.87% in 2025.
- Over 4 years, Gains from Investment Securities stood at $1.4 million in 2023, then slumped by 76.07% to $331000.0 in 2024, then slumped by 252.87% to -$506000.0 in 2025, then jumped by 119.17% to $97000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $97000.0, -$506000.0, and -$175000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -351,000.00 |
| Jun 30, 2026 | -351,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | -506,000.00 |
| Dec 31, 2025 | -506,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Sep 30, 2025 | -175,000.00 |
| Jun 30, 2025 | 350,000.00 |
| Jun 30, 2025 | 350,000.00 |
| Mar 31, 2025 | -584,000.00 |
| Mar 31, 2025 | -584,000.00 |
| Dec 31, 2024 | 331,000.00 |
| Dec 31, 2024 | 331,000.00 |
| Sep 30, 2024 | -233,000.00 |
| Sep 30, 2024 | -233,000.00 |
| Jun 30, 2024 | -507,000.00 |
| Jun 30, 2024 | -507,000.00 |
| Mar 31, 2024 | -1.36 Mn |
| Mar 31, 2024 | -1.36 Mn |